Abstract:Affected by differences in the pharmacokinetics (PK) of lenalidomide, the toxicity of lenalidomide varies among different patients, with serious toxicity leading to dose reduction or discontinuation. The differences in the PK of lenalidomide may be related to factors such as patients' physiological characteristics, pathological characteristics and gene polymorphisms etc., which may also affect its toxicity. The aim of this study is to establish a population pharmacokinetic (PPK) model of lenalidomide and explore factors associated with the adverse events (AEs) of lenalidomide from a PK perspective. Blood samples were collected by opportunistic blood collection. Drug concentrations were determined by using HPLC/MS and genotype of ABCB1 3435 C > T (rs1045642), ABCB1 1236 A > G (rs1128503) and ABCB1 2677 A > C/T (rs2032582) was tested by the first-generation DNA sequencing technology. NONMEM software and SPSS 26.0 software were used respectively to establish PPK model of lenalidomide and explore the correlation between PK parameters and the incidence of serious AEs of lenalidomide. 51 patients were enrolled in the PPK study, and one-compartment model with first-order absorption and elimination agreed well with the observed data. The significant covariate affecting lenalidomide apparent volume of distribution (V/F) were the gene polymorphism of ABCB1 3435 C > T and diet. Safety studies could be conducted in 39 patients. The V/F value in patients suffering from serious AEs was significantly higher than that in others ( median = 67.04 L vs 37.17 L, P = 0.033). According to the covariates screened, the incidence of serious AEs was higher in patients with genotype CT or TT at ABCB1 3435 C > T locus than that in patients with genotype CC ( P = 0.039). Additionally, V/F value was the highest in patients carrying genotype TT with postprandial medication, in whom the incidence of serious AEs was higher than others ( P = 0.037). In conclusion, the genotype of ABCB1 3435 C > T locus and diet had pharmacokinetically relevant impact on lenalidomide, which may also be related to the incidence of serious AEs. Patients with gene variants of CT or TT at ABCB1 3435 C > T locus may be more susceptible to serious AEs, and monitoring of adverse reactions should be particularly strengthened in patients who carried genotype TT with postprandial medication.

The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans.

A Pharmacogenetic Discovery: Cystamine Protects Against Haloperidol-Induced Toxicity and Ischemic Brain Injury.

Association Of Abcb1 Polymorphisms And Ulcerative Colitis Susceptibility

Genome-wide Association Mapping of Loci for Antipsychotic-Induced Extrapyramidal Symptoms in Mice.

Impact of ABCB1 gene polymorphism on opioid dependence and analgesic tolerance

Case-Control Association Study of Abcb1 Gene and Major Depressive Disorder in A Local Chinese Han Population

Comparative and Evolutionary Pharmacogenetics of ABCB1: Complex Signatures of Positive Selection on Coding and Regulatory Regions.

Abstract WP258: ZBTB7C is Associated with Severity of Infarction in Cerebral Ischemia

The MDR1/ABCB1 Gene, a High-Impact Risk Factor for Cardiac Transplant Rejection

Linkage Disequilibrium and Haplotype Architecture for Two ABC Transporter Genes (ABCC1 and ABCG2) in Chinese Population: Implications for Pharmacogenomic Association Studies

[Importance of HLA in Determining Individual Differences in the Onset of Adverse Drug Reactions]

Integrative Mouse and Human Studies Implicate ANGPT1 and ZBTB7C As Susceptibility Genes to Ischemic Injury.

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

Abcb1 C3435t Polymorphism and the Risk of Ischemic Heart Disease: A Meta-Analysis

Whole genome case-control study of central nervous system toxicity due to antimicrobial drugs

Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1

The Roles Of Variants In Human Multidrug Resistance (Mdr1) Gene And Their Haplotypes On Antiepileptic Drugs Response: A Meta-Analysis Of 57 Studies

Correlation between ABCB1 and OLIG2 polymorphisms and the severity and prognosis of patients with cerebral infarction

MDR1 Gene Polymorphisms and Clinical Relevance

Pharmacogenetics of ABCB1, CDA, DCK, GSTT1, GSTM1 and outcomes in a cohort of pediatric acute myeloid leukemia patients from Colombia

Atp1a2 and Kcnj9 are candidate genes underlying sensitivity to oxycodone-induced locomotor activation and withdrawal-induced anxiety-like behaviors in C57BL/6 substrains